Sphaeranthus indicus and Garcinia mangostana: The Obesity Research Combination

In 2013, two peer-reviewed papers reported weight-management outcomes for a proprietary extract blend prepared from Sphaeranthus indicus L. flower heads and Garcinia mangostana L. fruit rinds. One paper described an 8-week randomized trial in 60 adults with obesity; the other pooled two similarly designed 8-week trials involving 100 randomized participants, including the same 60-participant dataset. A separate 16-week randomized trial was published in 2016. These studies reported greater reductions in body weight and anthropometric measurements with the extract than with placebo when both groups also followed a controlled diet and walking program. The evidence concerns a specific standardized product and should not be generalized to ordinary Mundi preparations, mangosteen fruit, or other Garcinia species.

The Plants and Their Traditional Context

Sphaeranthus indicus L. is an accepted species in the Asteraceae family with a native range extending from southern China through tropical Asia to Australia. The Ayurvedic Pharmacopoeia of India identifies the dried leaf as Munditika and lists Mundi among its Sanskrit names and Gorakhmundi as a Hindi, Gujarati, and Punjabi name. The plant is described as an aromatic, much-branched herb occurring in damp and shady places throughout India.

The pharmacopoeial Ayurvedic profile of the leaf is broader than a simple bitter and pungent classification. Its rasa are Madhura, Katu, Tikta, and Kashaya; its guna is Laghu; its virya is Ushna; and its vipaka is Katu. Its listed actions include Medhya, Vishaghna, and Vata-Kapha-hara, while Medoroga is included among its therapeutic indications. The official monograph gives a dose of 3–6 g for the leaf drug. These specifications apply to the dried leaf, whereas the proprietary weight-management extract was manufactured from the flower heads; the two preparations are not pharmaceutically interchangeable.

Garcinia mangostana L., the purple mangosteen, is an accepted species in the Clusiaceae family. It is native to Peninsular Malaysia and Borneo and is now cultivated in other tropical regions. Its sweet pulp is eaten as food, while the fruit rind or pericarp contains numerous xanthones, with alpha-mangostin being one of the best-characterized constituents. The concentrated rind extract used in the clinical formula is therefore different from eating mangosteen fruit.

Garcinia mangostana should also be distinguished from Garcinia gummi-gutta (L.) N.Robson, for which Garcinia cambogia Desr. is a botanical synonym. The latter is a separate western Indian species commonly encountered in discussions of Vrikshamla. Ayurvedic names, properties, indications, and dosage traditions belonging to one Garcinia species cannot automatically be transferred to another merely because both belong to the same genus.

What the Proprietary Extract Contains

The clinical material, marketed as Meratrim, was made from separately extracted S. indicus flower heads and G. mangostana fruit rinds. In the 2016 publication, the two extracts were blended in a 3:1 ratio and then combined with excipients. The compounds 7-hydroxyfrullanolide and alpha-mangostin served as internal markers for monitoring consistency of the respective botanical extracts. The published method does not support describing each 400 mg capsule as 400 mg of Sphaeranthus plus 800 mg of Garcinia, nor does it report the formula as standardized to 0.5% 7-hydroxyfrullanolide and 60% total xanthones.

Participants in the human studies received 400 mg of the finished blend twice daily, providing a total daily dose of 800 mg. This dosage refers only to the studied extract and cannot be converted directly into a dose of raw Mundi leaf, flower powder, mangosteen rind, mangosteen juice, or a different commercial extract.

Mechanistic Findings in Cell Models

The mechanistic experiments tested the combined extract rather than proving that each pathway belonged exclusively to one plant or constituent. In the 2013 Obesity paper, the blend reduced lipid accumulation during differentiation of 3T3-L1 adipocytes and downregulated proteins associated with adipogenesis, including peroxisome proliferator-activated receptor gamma (PPAR-gamma), adipocyte differentiation-related protein, and CD36. It also altered adiponectin and perilipin expression in this laboratory model.

The 2016 publication reported that the combined extract reduced intracellular lipid accumulation and increased glycerol release from cultured adipocytes. It also reduced fatty acid synthase protein expression. In HepG2 cells, the blend increased phosphorylation of AMP-activated protein kinase at Thr172 and phosphorylation of acetyl-CoA carboxylase at Ser79. These observations are compatible with effects on adipocyte differentiation, lipolysis, and cellular lipid synthesis, but the pathway measurements were made in cultured cells rather than in the trial participants.

The published experiments therefore support discussing PPAR-gamma, fatty acid synthase, AMPK, and ACC as laboratory findings for the complete formulation. They do not establish that isolated 7-hydroxyfrullanolide suppresses PPAR-gamma in humans, that alpha-mangostin alone accounts for the clinical results, or that S. indicus inhibits 11-beta-hydroxysteroid dehydrogenase type 1. The proposed 11-beta-HSD1 and local cortisol mechanism is not part of the substantiated pharmacology of this formula.

A 2024 experiment in high-fat-diet-fed mice reported reduced fat accumulation and changes in pathways related to hepatic lipid synthesis and energy metabolism after administration of the blend. This animal work extends the preclinical characterization of the product but does not replace controlled human trials or establish long-term clinical outcomes.

Human Clinical Evidence

The first full clinical publication appeared in Obesity in May 2013, not in 2012. Sixty adults with BMI values between 30 and 40 kg/m² were randomized to 400 mg of the herbal blend or placebo twice daily for eight weeks. Participants in both groups received a 2,000-kcal daily diet and were instructed to walk for 30 minutes on five days each week. Compared with placebo, the active group had net reductions of 3.74 kg in body weight, 1.61 kg/m² in BMI, and 5.44 cm in waist circumference. Adverse events were described as mild and similarly distributed between groups.

A second 2013 publication in the Journal of Medicinal Food pooled two similarly designed eight-week trials involving 100 randomized participants, of whom 95 completed the studies. The pooled active group had mean reductions of 5.2 kg in weight, 2.2 kg/m² in BMI, 11.9 cm in waist circumference, and 6.3 cm in hip circumference. The paper also reported changes in adiponectin, fasting glucose, cholesterol, and triglycerides. Because this pooled analysis incorporated the participants from the 60-person Obesity trial, the two papers should not be counted as two completely independent replications.

The separate 2016 trial randomized 60 healthy overweight adults with a mean BMI of 28.3 kg/m², and 57 completed 16 weeks. Participants again took 400 mg twice daily or placebo while following an approximately 2,000-kcal diet and walking for 30 minutes on five days each week. At week 16, mean weight loss was 5.09 kg with the extract and 1.10 kg with placebo. Waist reductions were 9.97 versus 3.71 cm, and hip reductions were 10.38 versus 5.11 cm. The active group also had larger reductions in LDL cholesterol, triglycerides, and total cholesterol. Fasting glucose did not differ significantly between groups in this trial.

Clinical Study Comparison

The three publications differ in duration, participant population, and presentation of results. The 2013 pooled analysis includes the 60-participant trial reported separately in Obesity, while the 2016 study represents a later participant cohort.

Limitations and Interpretation

The clinical findings are promising but come from a small evidence base. The trials enrolled 60 to 100 participants, lasted between eight and sixteen weeks, and combined supplementation with prescribed calorie intake and regular walking. These designs permit comparison with a placebo group receiving the same lifestyle program, but they do not establish whether comparable results occur without dietary supervision, during longer use, or after the product is discontinued.

The two 2013 papers are partly dependent because the pooled publication includes the 60-person trial reported in Obesity. The 2016 trial added a separate cohort, but it was funded by Laila Nutraceuticals, which manufactured the study material. Independent, multicentre trials with larger samples, preregistered analyses, longer follow-up, and direct measurements of body composition would provide a stronger estimate of benefit and risk. In the 2016 study, too few participants completed the final DEXA assessment to determine reliably whether the lost weight represented fat mass, lean mass, or both.

The trials support only short-term conclusions about the exact extract, dose, and adult populations studied. They do not establish that Mundi leaf powder, Mundi flower powder, fresh mangosteen, mangosteen juice, isolated alpha-mangostin, or Garcinia gummi-gutta will reproduce the same outcomes. Likewise, cell-culture activation of AMPK or suppression of adipogenic proteins should not be presented as a demonstrated mechanism in human tissues.

Practical and Safety Considerations

The reported trials found mainly mild adverse events over eight to sixteen weeks. In the 2016 trial, minor complaints in the active group included dyspepsia, acidity, nausea, and gastritis; investigators did not classify them as supplement-related. These limited studies do not establish long-term safety, use during pregnancy or breastfeeding, pediatric use, or compatibility with all medicines and medical conditions.

Weight management should include assessment of diet, activity, sleep, metabolic health, medicines, and possible medical causes of weight change. Anyone considering a concentrated Sphaeranthus–mangosteen extract should consult a qualified Ayurvedic practitioner and healthcare provider, particularly when pregnant or breastfeeding, taking regular medication, living with a chronic illness, or preparing for surgery. The supplement should not replace prescribed treatment or individualized nutritional and medical care.

The verified record therefore supports describing this formulation as a proprietary botanical extract with several small, short-duration randomized trials and laboratory findings involving adipogenesis and lipid metabolism. Mundi contributes an authentic Ayurvedic context through its pharmacopoeial leaf monograph, but the commercial flower-head and mangosteen-rind blend is a modern extract formulation rather than a classical Ayurvedic combination. Its clinical results warrant further investigation without transferring its findings to other plant parts, species, products, or untested mechanisms.

References

1. Powo (powo.science.kew.org)
2. Ayurvedic Pharmacopoeia of India
3. Powo (powo.science.kew.org)
4. New insights into the anti-obesity activity of xanthones from Garcinia mangostana (2015), PubMed
5. Powo (powo.science.kew.org)
6. Powo (powo.science.kew.org)
7. Link (link.springer.com)
8. Efficacy and tolerability of a novel herbal formulation for weight management (2013)
9. The Herbal Blend of Sphaeranthus indicus and Garcinia mangostana Reduces Adiposity in High-Fat Diet Obese Mice (2024), PubMed
10. Efficacy and tolerability of a novel herbal formulation for weight management (2013), PubMed
11. Bladder cancer: second-line nab-paclitaxel for advanced urothelial carcinoma (2013), PubMed
12. Efficacy and tolerability of an herbal formulation for weight management (2013), PubMed
13. Efficacy and Tolerability of an Herbal Formulation for Weight Management (2013)
14. Efficacy and tolerability of Meratrim for weight management: a randomized, double-blind, placebo-controlled study in healthy overweight human subjects (2016), PubMed
15. Ten steps to establishing an e-consultation service to improve access to specialist care (2013), PubMed